• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reply to Çınar et al. Comment on "Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. 2022, , 874".回复 Çınar 等人对“Zamfir 等人。在 mRNA COVID-19 疫苗接种运动的背景下诊断出的血液系统恶性肿瘤：两例报告。2022 年，，874”的评论。
Medicina (Kaunas). 2022 Nov 1;58(11):1576. doi: 10.3390/medicina58111576.
2
Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. 2022, , 874.评 Zamfir 等人的研究：在 mRNA COVID-19 疫苗接种运动背景下诊断的血液系统恶性肿瘤：两例报告。2022，874.
Medicina (Kaunas). 2022 Nov 1;58(11):1575. doi: 10.3390/medicina58111575.
3
Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".作者对Mungmunpuntipantip等人就《四种不同新冠疫苗品牌免疫接种后报告的不良事件频率描述》的评论的回复
Drug Saf. 2022 Aug;45(8):925-926. doi: 10.1007/s40264-022-01207-x. Epub 2022 Jul 15.
4
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.在疫苗供应有限的情况下，优先为癌症患者接种 COVID-19 疫苗。
Cancer Discov. 2021 Feb;11(2):233-236. doi: 10.1158/2159-8290.CD-20-1817. Epub 2020 Dec 19.
5
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.血液恶性肿瘤患者 COVID-19 两剂疫苗系列的免疫原性：三例突破性感染报告。
Cancer Control. 2022 Jan-Dec;29:10732748211070720. doi: 10.1177/10732748211070720.
6
The precautionary principle in the COVID-19 vaccination campaign: The complicated relationship between the scientific community, medicines regulatory agencies and citizens.新冠疫苗接种运动中的预防原则：科学界、药品监管机构与公民之间的复杂关系。
Eur J Intern Med. 2022 Jul;101:118-119. doi: 10.1016/j.ejim.2022.03.011. Epub 2022 Mar 11.
7
Reply to 'Nail psoriasis: A rare mRNA COVID-19 vaccine reaction' by Lamberti A et al.对兰贝蒂A等人所著《甲银屑病：一种罕见的新型冠状病毒mRNA疫苗反应》的回复
J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e41-e42. doi: 10.1111/jdv.18537. Epub 2022 Aug 25.
8
Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to 'Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review' by Pauluzzi et al.大疱性类天疱疮与新冠病毒疫苗接种：对Pauluzzi等人所著《一名年轻男性接种新冠病毒mRNA疫苗后发生大疱性类天疱疮：一例报告及文献简要综述》的管理与治疗回应
J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e35-e36. doi: 10.1111/jdv.18503. Epub 2022 Aug 23.
9
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
10
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.美国基于mRNA的COVID-19疫苗接种后的心肌炎病例——回复
JAMA. 2022 May 24;327(20):2020-2021. doi: 10.1001/jama.2022.5134.

本文引用的文献

1
Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. 2022, , 874.评 Zamfir 等人的研究：在 mRNA COVID-19 疫苗接种运动背景下诊断的血液系统恶性肿瘤：两例报告。2022，874.
Medicina (Kaunas). 2022 Nov 1;58(11):1575. doi: 10.3390/medicina58111575.
2
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients.在既往感染过的血液系统癌症患者中接种疫苗后诱导针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的强大体液免疫。
Br J Haematol. 2022 Nov;199(3):463-467. doi: 10.1111/bjh.18429. Epub 2022 Sep 5.
3
Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis.新冠病毒mRNA疫苗在血液系统恶性肿瘤患者中的疗效和安全性：系统评价与荟萃分析
Front Oncol. 2022 Aug 5;12:951215. doi: 10.3389/fonc.2022.951215. eCollection 2022.
4
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.免疫功能低下的血液系统恶性肿瘤患者接种三剂 mRNA-1273 新冠疫苗后的抗体反应。
JAMA Oncol. 2022 Oct 1;8(10):1477-1483. doi: 10.1001/jamaoncol.2022.3227.
5
Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases.在 mRNA COVID-19 疫苗接种运动背景下诊断出的血液系统恶性肿瘤：两例报告。
Medicina (Kaunas). 2022 Jun 30;58(7):874. doi: 10.3390/medicina58070874.
6
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.血液恶性肿瘤患者的长程和持续性 COVID-19：从基础到临床。
Curr Opin Infect Dis. 2022 Aug 1;35(4):271-279. doi: 10.1097/QCO.0000000000000841. Epub 2022 Jul 5.
7
Hematological aspects of the COVID-19 syndrome.COVID-19 综合征的血液学方面。
Eur Rev Med Pharmacol Sci. 2022 Jun;26(12):4463-4476. doi: 10.26355/eurrev_202206_29086.
8
A needed boost against COVID-19 in lymphoma.淋巴瘤中对抗新冠病毒所需的助力。
Nat Cancer. 2022 May;3(5):526-527. doi: 10.1038/s43018-022-00374-1.
9
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.COVID-19 mRNA 疫苗在患有淋巴恶性肿瘤或抗 CD20 抗体治疗的患者中的应用：一项系统评价和荟萃分析。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e691-e707. doi: 10.1016/j.clml.2022.03.012. Epub 2022 Mar 28.
10
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report.BNT162b2 mRNA加强针后血管免疫母细胞性T细胞淋巴瘤快速进展：一例报告
Front Med (Lausanne). 2021 Nov 25;8:798095. doi: 10.3389/fmed.2021.798095. eCollection 2021.

回复 Çınar 等人对“Zamfir 等人。在 mRNA COVID-19 疫苗接种运动的背景下诊断出的血液系统恶性肿瘤：两例报告。2022 年，，874”的评论。

Reply to Çınar et al. Comment on "Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. 2022, , 874".

机构信息

Department of Oral and Maxillofacial Surgery, "Carol Davila" Central Military Emergency Hospital, 010825 Bucharest, Romania.

Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, "Titu Maiorescu" University, 031593 Bucharest, Romania.

出版信息

Medicina (Kaunas). 2022 Nov 1;58(11):1576. doi: 10.3390/medicina58111576.

DOI:10.3390/medicina58111576
PMID:36363533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9697811/
Abstract

We would like to thank Çınar et al. for their appreciation and insightful discussions presented in their comment [...].

摘要

我们感谢 Çınar 等人在其评论[...]中所表达的赞赏和富有见地的讨论。